HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

430.463

+8.7162.07%

Number of Gainers:27

Number of Losers:4

Number of Flat:3

PE:- -

High:431.911

Open:421.747

Low:421.747

Close:421.747

Loading ...

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody

THOMSON REUTERS

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.

CARsgen's Claudin18.2 CAR-T Therapy Satri-Cel Granted Breakthrough Therapy Designation by the Nmpa

THOMSON REUTERS

Immunotech Biopharm - Center for Drug Evaluation Agreed Group May Submit Application for Conditional Approval for Core Product Candidate, Eal

THOMSON REUTERS

Zai Lab Ltd : Leerink Partners Raises Target Price to $74 From $72

THOMSON REUTERS

Zai Lab Ltd Outlook FY 2025 Total Revenue $560 Mln to $590 Mln

THOMSON REUTERS

Zai Lab Ltd - Q4 Total Revenues $109.1 Million

THOMSON REUTERS

CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment

MT Newswires Live

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

THOMSON REUTERS

When Will Ocumension Therapeutics (HKG:1477) Turn A Profit?

Simply Wall St.

BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In China

CARsgen Therapeutics - Introduction of Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

THOMSON REUTERS

CARsgen Therapeutics - Investment Fund to Subscribe for Additional Registered Capital of Ucarsgen Biotech for RMB80 Mln

THOMSON REUTERS

InnoCare Pharma Anti-MS Drug Selected for Phase 3 Studies Following Efficacy, Safety Results

MT Newswires Live

Basecare Medical Unit to Collaborate with Rhea Labs on AI-Powered IVF Clinics

MT Newswires Live

HBM Joint Venture Strikes Licensing Deal to Advance Novel CRH Therapies

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":430.4633,"timestamp":1741248510375,"preClose":421.74713,"halted":0,"volume":196751826,"delay":0,"changeRate":0.020667,"change":8.716156,"pbRate":3.352817,"amount":2078205803,"amplitude":0.024099,"prevYearClose":331.1933,"fiveDayClose":431.446,"twentyDayClose":333.662,"turnoverRate":0.00762,"marketCap":241153069920,"floatMarketCap":226975358368,"peRate":-16.712341},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":431.91098,"amplitude":0.024099,"preClose":421.74713,"low":421.74713,"pbRate":"3.352817","latestPrice":430.4633,"volume":196751826,"delay":0,"open":421.74713,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":431.446,"twentyDayClose":333.662,"sixtyDayClose":346.493,"secType":"PLATE","market":"HK","turnoverRate":0.00762,"peRate":-16.712341,"marketCap":241153069920,"floatMarketCap":226975358368,"timestamp":1741248510375,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":27,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516608698","title":"CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608698?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:10","pubTimestamp":1741047002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA2RYCFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2516708635","title":"Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2516708635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516708635?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:06","pubTimestamp":1740974772,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Everest Medicines by retail investors implies that the general public has more...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limiteds-hkg1952-biggest-owners-are-retail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01952","MDCO","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2516930525","title":"CARsgen's Claudin18.2 CAR-T Therapy Satri-Cel Granted Breakthrough Therapy Designation by the Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2516930525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516930525?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:15","pubTimestamp":1740960905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUANP7GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1585","BK1587","02171","BK1161"],"gpt_icon":0},{"id":"2514312425","title":"Immunotech Biopharm - Center for Drug Evaluation Agreed Group May Submit Application for Conditional Approval for Core Product Candidate, Eal","url":"https://stock-news.laohu8.com/highlight/detail?id=2514312425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514312425?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:35","pubTimestamp":1740731756,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2514382028","title":"Zai Lab Ltd : Leerink Partners Raises Target Price to $74 From $72","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514382028?lang=en_us&edition=fundamental","pubTime":"2025-02-28 00:28","pubTimestamp":1740673738,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI25V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZLAB","BK4139","BK4526","BK1161","BK1588","BK4585","09688","BK4548","BK4588","BK1574","LU2488822045.USD","BK4531"],"gpt_icon":0},{"id":"2514877985","title":"Zai Lab Ltd Outlook  FY 2025 Total Revenue $560 Mln to $590 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514877985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514877985?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:07","pubTimestamp":1740654467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1588","09688","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2514487798","title":"Zai Lab Ltd - Q4 Total Revenues $109.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514487798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514487798?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:07","pubTimestamp":1740654467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1588","LU2488822045.USD","BK1161","09688"],"gpt_icon":0},{"id":"2514987977","title":"CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514987977","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514987977?lang=en_us&edition=fundamental","pubTime":"2025-02-27 18:13","pubTimestamp":1740651198,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics'  equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4141","BK4609","BK1161","LENZ","BK4139","LU0348723411.USD","IE00BMPRXR70.SGD","BK4585","BK1585","IE00BMPRXQ63.HKD","BK4543","BK1574","IE00BMPRXN33.USD","BK4588","02171","BK1587"],"gpt_icon":1},{"id":"2514270658","title":"Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for \"IO 2.0 + ADC\" Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514270658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514270658?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:58","pubTimestamp":1740646720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nTUA82CJGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0417516571.SGD","LU0348784397.USD","BK1161","BK1574","LU1720050803.USD","LU0348783233.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","09926"],"gpt_icon":0},{"id":"2514812683","title":"When Will Ocumension Therapeutics (HKG:1477) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514812683","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514812683?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:34","pubTimestamp":1740612844,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Ocumension Therapeutics...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1477/ocumension-therapeutics-shares/news/when-will-ocumension-therapeutics-hkg1477-turn-a-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01477","BK1574","LENZ","BK1191","BK4139"],"gpt_icon":0},{"id":"2514854243","title":"BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854243","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514854243?lang=en_us&edition=fundamental","pubTime":"2025-02-26 23:41","pubTimestamp":1740584468,"startTime":"0","endTime":"0","summary":"BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In ChinaFeb 26 (Reuters) - CARsgen Therapeutics 2171.HK:INTRODUCTION OF ZHUHAI SB XINCHUANG TO ACCELERATE ALLOGENEIC CAR-T CELL PROD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1161","BK1587","BK1574","02171"],"gpt_icon":0},{"id":"2514885860","title":"CARsgen Therapeutics - Introduction of Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514885860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514885860?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:50","pubTimestamp":1740577818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","02171","BK1574","BK1585"],"gpt_icon":0},{"id":"2514858139","title":"CARsgen Therapeutics -  Investment Fund to Subscribe for Additional Registered Capital of Ucarsgen Biotech for RMB80 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514858139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514858139?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:50","pubTimestamp":1740577818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","BK1574","BK1585","02171"],"gpt_icon":0},{"id":"2514837691","title":"InnoCare Pharma Anti-MS Drug Selected for Phase 3 Studies Following Efficacy, Safety Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837691","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837691?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:06","pubTimestamp":1740575217,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said the 80 mg once daily dose of its BTK inhibitor, Orelabrutinib, for the treatment of relapsing-remitting multiple sclerosis, was selected for phase 3 progressive multiple sclerosis studies following a demonstration of efficacy and safety profile.The company's phase 2 results were released at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum. These results will be presented as the on-site poster at the forum on Thursday, a Wednesday bourse filing said.Orelabrutinib is a selective brain-penetrant BTK inhibitor that inhibits B cell, microglia, and macrophage activation in the central nervous system along with inhibiting macrophage activation.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ1G4Q59.USD","LU2357305700.SGD","BK0239","09969","BK4504","BK1161","LU0912757837.SGD","LU2111349929.HKD","LU2271345857.HKD","LU0006306889.USD","LU0320765646.SGD","LU2347655156.SGD","BK4581","LU0314104364.USD","LU1720051108.HKD","LU1732800096.USD","LU1162221912.USD","LU0106831901.USD","BK4127","LU0267386448.USD","LU2133065610.SGD","LU1548497426.USD","LU0106261372.USD","LU1720051017.SGD","LU2028103732.USD","BK4585","LU0158827781.USD","BK4534","LU1074936037.SGD","LU1989772840.SGD","688428","LU0795875086.SGD","LU0795875169.SGD","LU1989772923.USD","LU2089284900.SGD","LU0971096721.USD","LU1668664300.SGD","LU0098860793.USD","LU1363072403.SGD","IE00BKVL7J92.USD","BK4516","LU1732799900.SGD","BK4588","LU0225283273.USD","LU2089283258.USD","BK1574","LU2023251221.USD","LU0158827948.USD"],"gpt_icon":0},{"id":"2514594838","title":"Basecare Medical Unit to Collaborate with Rhea Labs on AI-Powered IVF Clinics","url":"https://stock-news.laohu8.com/highlight/detail?id=2514594838","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514594838?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:53","pubTimestamp":1740567199,"startTime":"0","endTime":"0","summary":"Suzhou Basecare Medical's  subsidiary Genea Biomedx agreed to cooperate with Rhea Labs to establish model artificial intelligence-powered in vitro fertilization clinics.The five-year strategic cooperation will see the parties jointly expand the assisted reproductive industry markets across the US, Europe, South America, and Southeast Asia, a Tuesday bourse filing said.Under the tie-up, Genea Biomedx will provide medical products and comprehensive solutions to support the development of Rhea Labs' reproductive institutions and jointly collaborate to develop AI-powered new products.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK6100","BK1222","NPL.SI","02170","BK1597"],"gpt_icon":0},{"id":"2514005902","title":"HBM Joint Venture Strikes Licensing Deal to Advance Novel CRH Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2514005902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514005902?lang=en_us&edition=fundamental","pubTime":"2025-02-26 14:39","pubTimestamp":1740551973,"startTime":"0","endTime":"0","summary":"HBM Holdings'  joint venture with Boston Children's Hospital, HBM Alpha Therapeutics, agreed to collaborate with an unnamed business partner to advance novel therapies targeting corticotropin-releasing hormone or CRH for multiple disorders.Under the tie-up, the partner gets exclusive global rights to develop and commercialize HBM9013, an anti-CRH-neutralizing antibody. The license excludes China, Hong Kong, Taiwan and Macau.In return, HBM Alpha will receive up to $395 million, including upfront, development, regulatory, and commercial milestone payments, as well as tiered royalties on future net product sales.Additionally, HBM Alpha is entitled to a minority interest in the business partner, according to a Wednesday bourse filing.HBM9013 is an antibody program developed by the group for CRH-related disorders, including congenital adrenal hyperplasia, a group of diseases caused by gene mutations.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","LU1267930573.SGD","CRH","LU1506573853.SGD","LU2041044095.USD","LU1019632923.USD","LU1863844665.USD","BK1583","BK1574","LU0310800379.SGD","LU2298321311.HKD","LU1019634622.SGD","LU1880398554.USD","LU0314106906.USD","LU0708994859.HKD","LU0029864427.USD","LU1863844749.USD","LU1291149836.SGD","LU0868494708.USD","BK4011","LU1880398471.USD","02142","LU2463526074.USD","BK1161","GB00BDT5M118.USD","LU2360108059.USD","LU0238689110.USD","BK4185","LU0128525929.USD","LU0942090050.USD","LU1039938227.USD","LU0868494617.USD","LU1035777561.USD","LU1093756325.SGD","JYNT","LU2092937221.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":60}]}}